株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ペプチド治療の世界市場 (用途別・投与経路別・販売方式別):世界の産業分析・規模・シェア・動向・予測

Peptide Therapeutics Market (Application; Route of Administration; Type; Technology; Type of Molecule; API Peptide Type) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

発行 Transparency Market Research 商品コード 264243
出版日 ページ情報 英文 236 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.17円で換算しております。
Back to Top
ペプチド治療の世界市場 (用途別・投与経路別・販売方式別):世界の産業分析・規模・シェア・動向・予測 Peptide Therapeutics Market (Application; Route of Administration; Type; Technology; Type of Molecule; API Peptide Type) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
出版日: 2017年04月26日 ページ情報: 英文 236 Pages
概要

当レポートでは、世界のペプチド治療市場について、用途別、投与経路別、販売方式別、タイプ、APIペプチドおよび技術別に調査すると共に、地域別の市場動向や主要企業のプロファイルをも盛り込んでお届け致します。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 世界のペプチド治療市場の概要

  • イントロダクション
  • ペプチド治療市場の新たな動向
    • ペプチド製造技術の動向
    • ペプチド医薬原体 (API) の供給の動向
  • 市場力学
    • 促進要因
      • がん患者・糖尿病患者の人口増加による、新種ペプチド市場の成長促進
      • ペプチド治療の巨大な研究開発 (R&D) パイプラインによる市場成長促進
      • 技術進歩によるペプチド製造コストの引き下げ
    • 抑制要因
      • ペプチド構造の複雑化:APIメーカーにとっての大きな課題
      • 規制基準の欠落
    • 機会
      • パテントクリフに伴うジェネリック・ペプチド市場の成長見通し
      • バイオテクノロジー企業と大手製薬企業との提携による、さらなる成長の見通し
  • 規制シナリオ
  • ポーターのファイブフォース分析:世界のペプチド治療市場
  • イベント影響度の分析
  • 市場の誘因性の分析
  • 市場シェア分析

第4章 世界のペプチド治療市場:用途別

  • イントロダクション
    • 世界のペプチド治療市場の収益額:用途別 (通算9年間分)
  • がん
    • Zoladex (ゴセレリン)
    • Velcade (ボルテゾミブ)
    • Lupron/ Enantone/ Eligard (リュープロレリン)
    • その他
  • 心血管
    • Angiomax (ビバリルジン)
    • Integrilin (エプチフィバチド)
  • 中枢神経系
    • Copaxone (ガラティラメル)
  • 代謝障害
    • Victoza (リラグルチド)
    • Byetta (エクセナチド)
    • その他
  • 感染症
    • Incivek (テラプレビル)
    • Victrelis (ボセプレビル)
  • 血液疾患
    • Firazyr (イカチバント)
    • Kalbitor (エカランチド)
  • 胃腸障害
    • Gattex (テデュグルチド)
    • Linzess (リナクロチド)
  • 呼吸器系障害
  • 末端肥大症
  • その他の用途

第5章 世界のペプチド治療市場:投与経路別

  • イントロダクション
    • 世界のペプチド治療市場の収益額:投与経路別 (通算9年間分)
  • 非経口投与経路
  • 経口投与経路

第6章 (ステータスを提供することによって)、世界のペプチド治療市場:販売方式別

  • イントロダクション
    • 世界のペプチド治療市場の収益額:販売方式別 (通算9年間分)
  • ブランド・ペプチド薬治療
  • ジェネリック・ペプチド薬治療

第7章 世界のペプチド治療パイプライン製品:概要

  • イントロダクション
    • 世界のペプチド治療パイプライン製品の概要

第8章 世界のペプチド治療市場:地域別

  • イントロダクション
    • 世界のペプチド治療市場の収益額:地域別 (通算9年間分)
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域 (ROW)

第9章 提言

  • 厳密な研究開発 (R&D) 活動による新製品の獲得
  • 新興経済国での施設拡張
  • 企業買収を通じた急速な無機的成長

第10章 企業プロファイル

  • Amgen Inc.
    • 企業概要
    • 財務概要
    • 製品ポートフォリオ
    • 事業戦略
    • 最近の発展動向
  • AstraZeneca plc
  • Bachem Holding AG
  • CordenPharma International GmbH
  • Eli Lilly and Company
  • Ipsen S.A.
  • Lonza Group Ltd.
  • Merck & Co., Inc
  • Novartis AG
  • Novo Nordisk A/S
  • PolyPeptide Group
  • Roche Holdings AG
  • Sanofi
  • 武田薬品工業
  • Teva Pharmaceutical Industries Ltd.

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Title:
Peptide Therapeutics Market
(Application - Cancer, Metabolic, CVD, Respiratory, GIT, Anti-infective, Dermatology, CNS, and Renal; Route of Administration - Parenteral and Oral; Type - Innovative and Generic; Technology - Liquid Phase, Solid Phase, and Hybrid Phase; Type of Molecule - Vasopressin, Somatostatin, Calcitonin, and Natriuretic, Immunopeptide; API Peptide Type - In-house and CMO) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.

Global Peptide Therapeutics Market: Overview

This report provides in-depth region wise and country wise analysis of the peptide therapeutics market. Stakeholders of this report include manufacturers of peptide products, raw material suppliers, nutraceutical and cosmeceutical companies, food processing industries and new players planning to enter the market. It further provides qualitative and quantitative analysis of the global peptide therapeutics market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes major players with their reported revenue, market size, and forecast for the global peptide therapeutics market in major countries globally such as the U.S., Canada, Germany, France, United Kingdom, Switzerland, Spain, Japan, China, Brazil, Mexico, South Africa and Saudi Arabia

Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the peptide therapeutics with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors. Moreover, the report also includes pricing analysis for the major peptide drugs worldwide.

The market overview section comprises impact factors such as drivers, restraints, and opportunities for the global peptide therapeutics market. These factors would aid the stakeholders in establishing a strong foothold in the global peptide therapeutics market. Furthermore, the market overview section comprises key industry events, product overview, market attractiveness analysis and emerging trend in the peptide therapeutics market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and country wise to identify the most attractive market.

Global Peptide Therapeutics Market: Segmentation

The peptide therapeutics market has been segmented as by application, by route of administration, by type, by technology, by type of molecule, by API peptide type and by geography. Based on application, the market has been segmented into cancer, metabolic, CVD, respiratory, GIT, anti-infective, dermatology, CNS, renal and others. Based on route of administration, the market has been segmented into parenteral, oral and others.

Based on type, the market has been segmented into innovative and generic. Based on technology, the market has been segmented into liquid phase, solid phase and hybrid phase. Based on type of molecules, the market has been segmented into vasopressin, somatostatin, calcitonin, immunopeptide, natriuretic and others. Based on API peptide type, the market has been segmented into in-house and CMO.

Geographically, the peptide therapeutics market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., France, Italy, Spain, Rest of Europe, Japan, China, India, Rest of APAC, Brazil, Mexico, Rest of LATAM, South Africa, Saudi Arabia, Rest of MEA have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the peptide therapeutics market in various regions has been provided in this section. It also includes various ups and downs about particular country or geography that has impacted the overall market globally.

Global Peptide Therapeutics Market: Competitive Analysis

The report provides a detailed outline/blueprint of the peptide therapeutics market globally that will assist new companies in establishing their presence and market players in expanding their market share in the market. It concludes with the company profile section which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Sanofi, Teva Pharmaceutical Industries Ltd., Novo Nordisk, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Pfizer, Inc. and others.

The global peptide therapeutics market has been segmented into:

By Application

  • Cancer
  • Metabolic
  • CVD
  • Respiratory
  • GIT
  • Anti-infective
  • Dermatology
  • CNS
  • Renal
  • Others

By Route of Administration

  • Parenteral
  • Oral
  • Others

By Type

  • Innovative
  • Generic

By Technology

  • Liquid Phase
  • Solid Phase
  • Hybrid Phase

By Type of Molecule

  • Vasopressin
  • Somatostatin
  • Calcitonin
  • Immunopeptide
  • Natriuretic
  • Others

By API Peptide Type

  • In-house
  • CMO

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • Japan
    • China
    • India
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa (MEA)
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Table of Contents

1. Preface

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Objectives
  • 1.4. Key Questions Answered

2. Assumptions and Research Methodology

  • 2.1. Report Assumptions
  • 2.2. Acronyms Used
  • 2.3. Research Methodology

3. Executive Summary

  • 3.1. Global Peptide Therapeutics Market Snapshot
  • 3.2. Market Opportunity Map

4. Market Overview

  • 4.1. Product Overview
  • 4.2. Death Rate of Leukemia, by Country
  • 4.3. Death Rate of Cancer, by Country

5. Market Dynamics

  • 5.1. Drivers and Restraints Snapshot Analysis
  • 5.2. Drivers
  • 5.3. Restraints
  • 5.4. Opportunities
  • 5.5. Opportunity Analysis
  • 5.6. White Space Analysis
  • 5.7. Porter's Analysis
  • 5.8. Pipeline Analysis (Phase III)
  • 5.9. Peptide Drug Chemical Structure Trend Analysis
  • 5.10. Separation Media for Peptide Drug Manufacturing

6. Global Peptide Therapeutics Market Analysis, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
  • 6.3. Cancer
  • 6.4. Metabolic
  • 6.5. CVD
  • 6.6. Respiratory
  • 6.7. GIT
  • 6.8. Anti-infective
  • 6.9. Dermatology
  • 6.10. CNS
  • 6.11. Renal
  • 6.12. Others
  • 6.13. Key Trends
  • 6.14. Market Attractiveness Analysis

7. Global Peptide Therapeutics Market Analysis, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
  • 7.3. Parenteral
  • 7.4. Oral
  • 7.5. Others
  • 7.6. Key Trends
  • 7.7. Market Attractiveness Analysis

8. Global Peptide Therapeutics Market Analysis, by Type

  • 8.1. Key Findings
  • 8.2. Introduction
  • 8.3. Innovative
  • 8.4. Generic
  • 8.5. Key Trends
  • 8.6. Market Attractiveness Analysis

9. Global Peptide Therapeutics Market Analysis, by Technology

  • 9.1. Key Findings
  • 9.2. Introduction
  • 9.3. Liquid Phase
  • 9.4. Solid Phase
  • 9.5. Hybrid Phase
  • 9.6. Market Attractiveness Analysis

10. Global Peptide Therapeutics Market Analysis, by Type of Molecule

  • 10.1. Key Findings
  • 10.2. Introduction
  • 10.3. Vasopressin
  • 10.4. Somatostatin
  • 10.5. Calcitonin
  • 10.6. Immunopeptide
  • 10.7. Natriuretic
  • 10.8. Others
  • 10.9. Market Attractiveness Analysis

11. Global API Peptide Therapeutics Market Analysis, by Type

  • 11.1. Key Findings
  • 11.2. Introduction
  • 11.3. In-house
  • 11.4. CMO
  • 11.5. Market Attractiveness Analysis

12. Global Peptide Therapeutics Market Analysis, by Region

  • 12.1. Regulatory Framework
  • 12.2. North America
  • 12.3. Europe
  • 12.4. Asia Pacific
  • 12.5. Latin America
  • 12.6. Middle East & Africa
  • 12.7. Market Attractiveness Analysis

13. North America Peptide Therapeutics Market Analysis

  • 13.1. North America Peptide Therapeutics Market Size Forecast, By Country, 2016-2024
  • 13.2. North America Peptide Therapeutics Therapy Market Size Forecast, By Application, 2016-2024
  • 13.3. North America Peptide Therapeutics Market Size Forecast, By Route of Administration, 2016-2024
  • 13.4. North America Peptide Therapeutics Market Size Forecast, By Type, 2016-2024
  • 13.5. North America Peptide Therapeutics Market Size Forecast, By Technology, 2016-2024
  • 13.6. North America Peptide Therapeutics Market Attractiveness Analysis, 2016-2024

14. Europe Peptide Therapeutics Market Analysis

  • 14.1. Europe Peptide Therapeutics Market Size Forecast, By Country, 2016-2024
  • 14.2. Europe Peptide Therapeutics Therapy Market Size Forecast, By Application, 2016-2024
  • 14.3. Europe Peptide Therapeutics Market Size Forecast, By Route of Administration, 2016-2024
  • 14.4. Europe Peptide Therapeutics Market Size Forecast, By Type, 2016-2024
  • 14.5. Europe Peptide Therapeutics Market Size Forecast, By Technology, 2016-2024
  • 14.6. Europe Peptide Therapeutics Market Attractiveness Analysis, 2016-2024

15. Asia Pacific Peptide Therapeutics Market Analysis

  • 15.1. Asia Pacific Peptide Therapeutics Market Size Forecast, By Country, 2016-2024
  • 15.2. Asia Pacific Peptide Therapeutics Therapy Market Size Forecast, By Application, 2016-2024
  • 15.3. Asia Pacific Peptide Therapeutics Market Size Forecast, By Route of Administration, 2016-2024
  • 15.4. Asia Pacific Peptide Therapeutics Market Size Forecast, By Type, 2016-2024
  • 15.5. Asia Pacific Peptide Therapeutics Market Size Forecast, By Technology, 2016-2024
  • 15.6. Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, 2016-2024

16. Latin America Peptide Therapeutics Market Analysis

  • 16.1. Latin America Peptide Therapeutics Market Size Forecast, By Country, 2016-2024
  • 16.2. Latin America Peptide Therapeutics Therapy Market Size Forecast, By Application, 2016-2024
  • 16.3. Latin America Peptide Therapeutics Market Size Forecast, By Route of Administration, 2016-2024
  • 16.4. Latin America Peptide Therapeutics Market Size Forecast, By Type, 2016-2024
  • 16.5. Latin America Peptide Therapeutics Market Size Forecast, By Technology, 2016-2024
  • 16.6. Latin America Peptide Therapeutics Market Attractiveness Analysis, 2016-2024
  • 16.7. Latin America Peptide Therapeutics Market Attractiveness Analysis

17. Middle East & Africa Peptide Therapeutics Market Analysis

  • 17.1. Middle East & Africa Peptide Therapeutics Market Size Forecast, By Country, 2016-2024
  • 17.2. Middle East & Africa Peptide Therapeutics Therapy Market Size Forecast, By Application, 2016-2024
  • 17.3. Middle East & Africa Peptide Therapeutics Market Size Forecast, By Route of Administration, 2016-2024
  • 17.4. Middle East & Africa Peptide Therapeutics Market Size Forecast, By Type, 2016-2024
  • 17.5. Middle East & Africa Peptide Therapeutics Market Size Forecast, By Technology, 2016-2024
  • 17.6. Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, 2016-2024

18. Competitive Landscape

  • 18.1. Market Share Analysis by Company (2015)
  • 18.2. Competition Matrix
    • 18.2.1. Teva Pharmaceutical Industries Ltd.
    • 18.2.2. GlaxoSmithKline
    • 18.2.3. Novartis AG
    • 18.2.4. Pfizer, Inc.
    • 18.2.5. F. Hoffmann-La Roche Ltd.
    • 18.2.6. Bachem Holding AG
    • 18.2.7. Sanofi

19. Company Profiles

  • 19.1. Amgen, Inc.
    • 19.1.1. Company Details
    • 19.1.2. Company Description
    • 19.1.3. Business Overview
    • 19.1.4. SWOT Analysis
    • 19.1.5. Financial Analysis
    • 19.1.6. Strategic Overview
  • 19.2. Bachem Holding AG
    • 19.2.1. Company Details
    • 19.2.2. Company Description
    • 19.2.3. Business Overview
    • 19.2.4. SWOT Analysis
    • 19.2.5. Financial Analysis
    • 19.2.6. Strategic Overview
  • 19.3. Eli Lilly and Company
    • 19.3.1. Company Details
    • 19.3.2. Company Description
    • 19.3.3. Business Overview
    • 19.3.4. SWOT Analysis
    • 19.3.5. Financial Analysis
    • 19.3.6. Strategic Overview
  • 19.4. F. Hoffmann-La Roche Ltd.
    • 19.4.1. Company Details
    • 19.4.2. Company Description
    • 19.4.3. Business Overview
    • 19.4.4. SWOT Analysis
    • 19.4.5. Financial Analysis
    • 19.4.6. Strategic Overview
  • 19.5. GlaxoSmithKline Plc
    • 19.5.1. Company Details
    • 19.5.2. Company Description
    • 19.5.3. Business Overview
    • 19.5.4. SWOT Analysis
    • 19.5.5. Financial Analysis
    • 19.5.6. Strategic Overview
  • 19.6. Novartis AG
    • 19.6.1. Company Details
    • 19.6.2. Company Description
    • 19.6.3. Business Overview
    • 19.6.4. SWOT Analysis
    • 19.6.5. Financial Analysis
    • 19.6.6. Strategic Overview
  • 19.7. Pfizer, Inc.
    • 19.7.1. Company Details
    • 19.7.2. Company Description
    • 19.7.3. Business Overview
    • 19.7.4. SWOT Analysis
    • 19.7.5. Financial Analysis
    • 19.7.6. Strategic Overview
  • 19.8. Sanofi
    • 19.8.1. Company Details
    • 19.8.2. Company Description
    • 19.8.3. Business Overview
    • 19.8.4. SWOT Analysis
    • 19.8.5. Financial Analysis
    • 19.8.6. Strategic Overview
  • 19.9. Takeda Pharmaceutical Company Limited
    • 19.9.1. Company Details
    • 19.9.2. Company Description
    • 19.9.3. Business Overview
    • 19.9.4. SWOT Analysis
    • 19.9.5. Financial Analysis
    • 19.9.6. Strategic Overview
  • 19.10. Teva Pharmaceutical Industries Ltd.
    • 19.10.1. Company Details
    • 19.10.2. Company Description
    • 19.10.3. Business Overview
    • 19.10.4. SWOT Analysis
    • 19.10.5. Financial Analysis
    • 19.10.6. Strategic Overview

List of Tables

  • TABLE 1: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2016-2024
  • TABLE 2: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2016-2024
  • TABLE 3: Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 4: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2016-2024
  • TABLE 5: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2016-2024
  • TABLE 6: API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 7: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Region, 2016-2024
  • TABLE 8: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • TABLE 9: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2016-2024
  • TABLE 10: North America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2016-2024
  • TABLE 11: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 12: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2016-2024
  • TABLE 13: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2016-2024
  • TABLE 14: North America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 15: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • TABLE 16: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2016-2024
  • TABLE 17: Europe Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2016-2024
  • TABLE 18: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 19: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2016-2024
  • TABLE 20: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2016-2024
  • TABLE 21: Europe API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 22: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • TABLE 23: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2016-2024
  • TABLE 24: Asia Pacific Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2016-2024
  • TABLE 25: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 26: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2016-2024
  • TABLE 27: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2016-2024
  • TABLE 28: Asia Pacific API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 29: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • TABLE 30: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2016-2024
  • TABLE 31: Latin America Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2016-2024
  • TABLE 32: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 33: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2016-2024
  • TABLE 34: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2016-2024
  • TABLE 35: Latin America API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 36: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016-2024
  • TABLE 37: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Application, 2016-2024
  • TABLE 38: Middle East & Africa Peptide Therapeutics Market Size (US$) Forecast, by Route of Administration, 2016-2024
  • TABLE 39: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024
  • TABLE 40: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Technology, 2016-2024
  • TABLE 41: Middle East & Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type of Molecule, 2016-2024
  • TABLE 42: Middle East & Africa API Peptide Therapeutics Market Size (US$ Mn) Forecast, by Type, 2016-2024

List of Figures

  • FIG. 1: Global Peptide Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
  • FIG. 2: Global Cancer Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 3: Global Metabolic Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 4: Global CVD Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 5: Global Respiratory Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 6: Global GIT Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 7: Global Anti-infective Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 8: Global Dermatology Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 9: Global CNS Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 10: Global Renal Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 11: Global Others Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 12: Peptide Therapeutics Market Attractiveness Analysis, by Application
  • FIG. 13: Global Peptide Therapeutics Market Value Share Analysis, by Route of Administration, 2015 and 2024
  • FIG. 14: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Parenteral, 2016-2024
  • FIG. 15: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Oral, 2016-2024
  • FIG. 16: Global Peptide Therapeutics Market Size (US$ Mn) Forecast, by Others, 2016-2024
  • FIG. 17: Global Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration
  • FIG. 18: Peptide Therapeutics Market Value Share Analysis, by Type, 2015 and 2024
  • FIG. 19: Innovative Peptide Therapeutics Market Size (US$ Mn), 2016-2024
  • FIG. 20: Generic Peptide Therapeutics Market Size (US$ Mn), 2016-2024
  • FIG. 21: Peptide Therapeutics Market Attractiveness Analysis, by Type
  • FIG. 22: Global Peptide Therapeutics Market Value Share Analysis, by Technology, 2015 and 2024
  • FIG. 23: Global Liquid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 24: Global Solid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 25: Global Hybrid Phase Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 26: Global Peptide Therapeutics Market Attractiveness Analysis, by Technology
  • FIG. 27: Global Peptide Therapeutics Market Value Share Analysis, by Type of Molecules, 2015 and 2024
  • FIG. 28: Global Vasopressin Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 29: Global Somatostatins Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 30: Global Calcitonin Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 31: Global Immunopeptides Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 32: Global Natriuretic Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 33: Global Other Peptides Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 34: Peptide Therapeutics Market Attractiveness Analysis, by Type of Molecule
  • FIG. 35: API Peptide Therapeutics Market Value Share Analysis, by Type, 2015 and 2024
  • FIG. 36: In-house Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 37: CMO Peptide Therapeutics Market Size Forecast (US$ Mn), 2016-2024
  • FIG. 38: API Peptide Therapeutics Market Attractiveness Analysis, by Type
  • FIG. 39: North America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 40: Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 41: Asia Pacific Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 42: Latin America Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 43: MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 44: Global Peptide Therapeutics Market Attractiveness Analysis, by Region
  • FIG. 45: U.S. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 46: Canada Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 47: North America Peptide Therapeutics Market Attractiveness Analysis, by Country
  • FIG. 48: North America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration
  • FIG. 49: North America Peptide Therapeutics Market Attractiveness Analysis, by Type
  • FIG. 50: North America Peptide Therapeutics Market Attractiveness Analysis, by Technology
  • FIG. 51: Germany Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 52: U.K. Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 53: France Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 54: Italy Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 55: Spain Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 56: Rest of Europe Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 57: Europe Peptide Therapeutics Market Attractiveness Analysis, by Country
  • FIG. 58: Europe Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration
  • FIG. 59: Europe Peptide Therapeutics Market Attractiveness Analysis, by Type
  • FIG. 60: Europe Peptide Therapeutics Market Attractiveness Analysis, by Technology
  • FIG. 61: Japan Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 62: China Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 63: India Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 64: Rest of APAC Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 65: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Country
  • FIG. 66: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration
  • FIG. 67: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Type
  • FIG. 68: Asia Pacific Peptide Therapeutics Market Attractiveness Analysis, by Technology
  • FIG. 69: Brazil Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 70: Mexico Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 71: Rest of LATAM Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 72: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Country
  • FIG. 73: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration
  • FIG. 74: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Type
  • FIG. 75: Latin America Peptide Therapeutics Market Attractiveness Analysis, by Technology
  • FIG. 76: South Africa Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 77: Saudi Arabia Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 78: Rest of MEA Peptide Therapeutics Market Size (US$ Mn) Forecast, 2016-2024
  • FIG. 79: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Country
  • FIG. 80: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Route of Administration
  • FIG. 81: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Type
  • FIG. 82: Middle East & Africa Peptide Therapeutics Market Attractiveness Analysis, by Technology
  • FIG. 83: Peptide Therapeutics Market Share Analysis By Company (2015)
Back to Top